Table 2. Comparison of laboratory and functional parameters between nintedanib and pirfenidone treatment groups in IPF patients.
|
Parameter |
Nintedanib (n = 41) |
Pirfenidone (n = 52) |
P |
|
Arterial blood gas measurements |
- |
- |
- |
|
- pH |
7.41±0.04 |
7.42±0.04 |
0.361 |
|
- pO2 (mmHg) |
71.65±5.85 |
75.47±6.15 |
0.734 |
|
- pCO2 (mmHg) |
34.85±3.94 |
36.13±3.92 |
0.391 |
|
Pulmonary function tests |
- |
- |
- |
|
- FVC (%) |
77.37±18.68 |
72.00±17.67 |
0.160 |
|
- FEV1 (%) |
82.63±19.46 |
77.15±16.93 |
0.150 |
|
- FEV1/FVC (%) |
86.02±7.98 |
83.54±11.84 |
0.219 |
|
- DLCO (%) |
55.21±16.64 |
54.06±16.70 |
0.493 |
|
6 minute walk test, (m) |
359.89±42.23 |
347.91±41.47 |
0.565 |
|
6 minute walk test, % |
65.92±14.60 |
65.08±15.20 |
0.805 |
|
GAP score |
3.39±1.61 |
4.21±1.14 |
0.007 |
IPF: Idiopathic pulmonary fibrosis, PFT: Pulmonary function tests, FVC: Forced vital capacity, FEV1/FVC: Ratio of forced expiratory volume in the first second to forced vital capacity, DLCO: Diffusing capacity for carbon monoxide, m: Meter, GAP: Gender, Age, Physiology Score